Monoclonal Antibody Shows Promise for PSC Treatment
A new monoclonal antibody therapy has shown encouraging results for patients suffering from primary sclerosing cholangitis (PSC), a rare and progressive liver disease with no approved medical treatment. Researchers from the University of California, Davis have reported that the experimental drug nebokitug appears safe and potentially effective in reducing liver inflammation and fibrosis. The findings have been published in the American Journal of Gastroenterology. Unmet Need in Primary Sclerosing Cholangitis PSC is a chronic condition characterised by inflammation and scarring of the bile ducts, leading to bile accumulation and progressive liver damage. Over time, the disease can result in cirrhosis, liver failure and the need for transplantation. The cause of PSC remains unclear, though most patients also have inflammatory bowel disease, suggesting a gut–liver immune link. Current management is limited to symptom control and monitoring of complications, as no drug therapy has be...